Sex-Based Differences in Outcomes of Coronavirus Disease 2019 (COVID-19) in Korea

Kim, Jiyoung; Heo, Narae; Kang, Hoonjong

doi:10.1016/j.anr.2022.07.003

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although studies are limited, vaccinated people report less headache than those unvaccinated [30]. Several studies describe headache being more frequent in women [19,23,31–33], at a younger age [19,34,35] and in patients with personal history of migraine [23,36,37]. Concerning ethnicity, Hispanic people seem to report headache more frequently [38], although more data are needed.…”

Section: Resultsmentioning

confidence: 99%

Headaches and facial pain attributed to SARS‐CoV‐2 infection and vaccination: a systematic review

Mitsikostas,

Caronna,

De Tommaso

et al. 2024

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeThe aim was to provide insights to the characteristics of headache in the context of COVID‐19 on behalf of the Headache Scientific Panel and the Neuro‐COVID‐19 Task Force of the European Academy of Neurology (EAN) and the European Headache Federation (EHF).MethodsFollowing the Delphi method the Task Force identified six relevant questions and then conducted a systematic literature review to provide evidence‐based answers and suggest specific diagnostic criteria.ResultsNo data for facial pain were identified in the literature search. (1) Headache incidence during acute COVID‐19 varies considerably, with higher prevalence rates in prospective compared to retrospective studies (28.9%–74.6% vs. 6.5%–34.0%). (2) Acute COVID‐19 headache is usually bilateral or holocranial and often moderate to severe with throbbing pain quality lasting 2–14 days after first signs of COVID‐19; photo‐phonophobia, nausea, anosmia and ageusia are common associated features; persistent headache shares similar clinical characteristics. (3) Acute COVID‐19 headache is presumably caused by immune‐mediated mechanisms that activate the trigeminovascular system. (4) Headache occurs in 13.3%–76.9% following SARS‐CoV‐2 vaccination and occurs more often amongst women with a pre‐existing primary headache; the risk of developing headache is higher with the adenoviral‐vector‐type vaccines than with other preparations. (5) Headache related to SARS‐CoV‐2 vaccination is mostly bilateral, and throbbing, pressing, jolting or stabbing. (6) No studies have been conducted investigating the underlying mechanism of headache attributed to SARS‐CoV‐2 vaccines.ConclusionThe results of this joint EAN/EHF initiative provide a framework for a better understanding of headache in the context of SARS‐CoV‐2 infection and vaccination.

show abstract